Management of Rhinitis: Guidelines, Evidence Basis, and Systematic Clinical Approach for What We Do

Immunology and Allergy Clinics of North America

Volumn 31, Issue 3, 2011, Pages 619-634

  Dykewicz, Mark S ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

Diagnosis; Guidelines; Management; Medication; Rhinitis; Treatment

Indexed keywords

ANTIHISTAMINIC AGENT; AZELASTINE; CHOLINERGIC RECEPTOR BLOCKING AGENT; CORTICOSTEROID; CROMOGLYCATE DISODIUM; DECONGESTIVE AGENT; DESLORATADINE; FEXOFENADINE; FLUTICASONE PROPIONATE; IPRATROPIUM BROMIDE; LEUKOTRIENE RECEPTOR BLOCKING AGENT; LORATADINE; MONTELUKAST;

ALLERGIC RHINITIS; ASTHMA; CLINICAL DECISION MAKING; CLINICAL EFFECTIVENESS; CLINICAL EVALUATION; COMBINATION CHEMOTHERAPY; CONCEPTUAL FRAMEWORK; DIFFERENTIAL DIAGNOSIS; DISEASE DURATION; DISEASE SEVERITY; DRUG CHOICE; DRUG HALF LIFE; DRUG INDICATION; DRUG POTENTIATION; DRUG SAFETY; EVIDENCE BASED PRACTICE; HAY FEVER; HEART PALPITATION; HUMAN; HYPERTENSION; INSOMNIA; IRRITABILITY; MEDICAL HISTORY; MONOTHERAPY; NOSE SEPTUM PERFORATION; PATIENT ATTITUDE; PERENNIAL RHINITIS; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; RHINORRHEA; RISK REDUCTION; SEDATION; SELF MEDICATION; SIDE EFFECT; SKIN TEST; SOMNOLENCE; SYMPTOMATOLOGY; TASTE DISORDER; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; VASOMOTOR RHINITIS;

HUMANS; HYPERSENSITIVITY; INDIVIDUALIZED MEDICINE; RHINITIS; RHINITIS, ALLERGIC, PERENNIAL; RHINITIS, ALLERGIC, SEASONAL; TREATMENT OUTCOME;

EID: 79960012709     PISSN: 08898561     EISSN: 15578607     Source Type: Journal    
DOI: 10.1016/j.iac.2011.05.002     Document Type: Review

References (37)

1. Wallace D.V., Dykewicz M.S., Bernstein D.I., et al. The diagnosis and management of rhinitis: an updated practice parameter. J Allergy Clin Immunol 2008, 122:S1-S84. The Joint Force on Practice Parameters, representing the AAAAI, ACAAI, JCAAI, PMID: 18662584.
2. Bousquet J., Khaltaev N., Cruz A.A., et al. Allergic rhinitis and its impact on asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen). Allergy 2008, 63(Suppl 86):8-160.
3. Khan D.A. Allergic rhinitis with negative skin tests: does it exist?. Allergy Asthma Proc 2009, 30(5):465-469.
4. Benninger M., Farrar J.R., Blaiss M., et al. Evaluating approved medications to treat allergic rhinitis in the United States: an evidence-based review of efficacy for nasal symptoms by class. Ann Allergy Asthma Immunol 2010, 104(1):13-29.
5. Dykewicz M.S., Fineman S., Skoner D.P., et al. Diagnosis and management of rhinitis: complete guidelines of the joint task force on practice parameters in allergy, asthma and immunology. Ann Allergy Asthma Immunol 1998, 81:478-518.
6. Bousquet J., Van Cauwenberge P., Khaltaev N. Allergic rhinitis and its impact on asthma. J Allergy Clin Immunol 2001, 108:S147-S334.
7. Brozek J.L., Bousquet J., Baena-Cagnani C.E., et al. Allergic rhinitis and its impact on asthma (ARIA) guidelines: 2010 revision. J Allergy Clin Immunol 2010, 126:466-476.
8. Church M.K., Watelet J.B., Belgian SIGMA Group Treating allergic rhinitis: continuous versus on-demand regime? Executive summary of the Supportive Initiatives for the Global Management of Allergy (SIGMA): report from the Belgian Working Group. B-ENT 2009, 5(Suppl 12):1-25.
9. Stempel D.A., Thomas M. Treatment of allergic rhinitis: an evidence based evaluation of nasal corticosteroids versus nonsedating antihistamines. Am J Manag Care 1998, 4:89-96.
10. Weiner J.M., Abramson M.J., Puy R.M. Intranasal corticosteroids versus oral H1 receptor antagonists in allergic rhinitis: systematic review of randomized controlled trials. BMJ 1998, 317:1624-1629.
11. Yanez A., Rodrigo G.J. Intranasal corticosteroids versus topical H1 receptor antagonists for the treatment of allergic rhinitis: a systematic review with meta-analysis. Ann Allergy Asthma Immunol 2002, 89:479-484.
12. Settipane R.A. Rhinitis: a dose of epidemiological reality. Allergy Asthma Proc 2003, 24:147-154.
13. Settipane R.A., Charnock D.R. Epidemiology of rhinitis: allergic and nonallergic. Clin Allergy Immunol 2007, 19:23-34.
14. Agarwal M.K., Swanson M.C., Reed C.E., et al. Immunochemical quantitation of airborne short ragweed, Alternaria, antigen E, and Alt-I allergens: a two-year prospective study. J Allergy Clin Immunol 1983, 72(1):40-45.
15. Blaiss M.S. Important aspects in management of allergic rhinitis: compliance, cost, and quality of life. Allergy Asthma Proc 2003, 24(4):231-238.
16. Bollinger M.E., Diette G.B., Chang C.L., et al. Patient characteristics and prescription fill patterns for allergic rhinitis medications, with a focus on montelukast, in a commercially insured population. Clin Ther 2010, 32(6):1093-1102.
17. Pullerits T., Praks L., Ristioja V., et al. Comparison of a nasal glucocorticoid, antileukotriene, and a combination of antileukotriene and antihistamine in the treatment of seasonal allergic rhinitis. J Allergy Clin Immunol 2002, 109:949-955.
18. Meltzer E.O., Malmstrom K., Lu S., et al. Concomitant montelukast and loratadine as treatment for seasonal allergic rhinitis: a randomized, placebo-controlled clinical trial. J Allergy Clin Immunol 2000, 105:917-922.
19. Nayak A.S., Philip G., Lu S., et al. Efficacy and tolerability of montelukast alone or in combination with loratadine in seasonal allergic rhinitis: a multicenter, randomized, double-blind, placebo-controlled trial performed in the fall. Ann Allergy Asthma Immunol 2002, 88:592-600.
20. Zubizaretta J. Azatadine maleate/pseudoephedrine sulfate repetabs versus placebo in the treatment of severe perennial allergic rhinitis. J Int Med Res 1980, 8:395-399.
21. Bronsky E., Boggs P., Findlay S., et al. Comparative efficacy and safety of a once-daily loratadine pseudoephedrine combination versus its components alone and placebo in the management of seasonal allergic rhinitis. J Allergy Clin Immunol 1995, 96:139-147.
22. Williams B.O., Hull H., McSorley P., et al. Efficacy of acrivastine plus pseudoephedrine for symptomatic relief of seasonal allergic rhinitis due to mountain cedar. Ann Allergy Asthma Immunol 1996, 76:432-438.
23. Grossman J., Bronsky E.A., Lanier B.Q., et al. Loratadinepseudoephedrine combination versus placebo in patients with seasonal allergic rhinitis. Ann Allergy 1989, 63:317-321.
24. Wellington K., Jarvis B. Cetirizine/pseudoephedrine. Drugs 2001, 61:2231-2240. [discussion: 2241-2].
25. Berkowitz R.B., McCafferty F., Lutz C., et al. Fexofenadine HCl 60 mg/pseudoephedrine HCl 120 mg has a 60-minute onset of action in the treatment of seasonal allergic rhinitis symptoms, as assessed in an allergen exposure unit. Allergy Asthma Proc 2004, 25:335-343.
26. Rodrigo G.J., Yanez A. The role of antileukotriene therapy in seasonal allergic rhinitis: a systematic review of randomized trials. Ann Allergy Asthma Immunol 2006, 96:779-786.
27. Wilson A.M., O'Byrne P.M., Parameswaran K. Leukotriene receptor antagonists for allergic rhinitis: a systematic review and meta-analysis. Am J Med 2004, 116:338-344.
28. Wilson A.M., Orr L.C., Sims E.J., et al. Effects of monotherapy with intranasal corticosteroid or combined oral histamine and leukotriene receptor antagonists in seasonal allergic rhinitis. Clin Exp Allergy 2001, 31:61-68.
29. Saengpanich S., deTineo M., Naclerio R.M., et al. Fluticasone nasal spray and the combination of loratadine and montelukast in seasonal allergic rhinitis. Arch Otolaryngol Head Neck Surg 2003, 129:557-562.
30. Ratner P.H., van Bavel J.H., Martin B.G., et al. A comparison of the efficacy of fluticasone propionate aqueous nasal spray and loratadine, alone and in combination, for the treatment of seasonal allergic rhinitis. J Fam Pract 1998, 47:118-125.
31. Barnes M.L., Ward J.H., Fardon T.C., et al. Effects of levocetirizine as add-on therapy to fluticasone in seasonal allergic rhinitis. Clin Exp Allergy 2006, 36:676-684.
32. Di Lorenzo G., Pacor M.L., Pellitteri M.E., et al. Randomized placebo-controlled trial comparing fluticasone aqueous nasal spray in mono-therapy, fluticasone plus cetirizine, fluticasone plus montelukast and cetirizine plus montelukast for seasonal allergic rhinitis. Clin Exp Allergy 2004, 34:259-267.
33. Juniper E.F., Guyatt G.H., Ferrie P.J., et al. First-line treatment of seasonal (ragweed) rhinoconjunctivitis: a randomized management trial comparing a nasal steroid spray and a nonsedating antihistamine. CMAJ 1997, 156:1123-1131.
34. Dockhorn R., Aaronson D., Bronsky E., et al. Ipratropium bromide nasal spray 0.03% and beclomethasone nasal spray alone and in combination for the treatment of rhinorrhea in perennial rhinitis. Ann Allergy Asthma Immunol 1999, 82:349-359.
35. Ratner P.H., Hampel F., Van Bavel J., et al. Combination therapy with azelastine hydrochloride nasal spray and fluticasone propionate nasal spray in the treatment of patients with seasonal allergic rhinitis. Ann Allergy Asthma Immunol 2008, 100(1):74-81.
36. Hampel F.C., Ratner P.H., Van Bavel J., et al. Double-blind, placebo-controlled study of azelastine and fluticasone in a single nasal spray delivery device. Ann Allergy Asthma Immunol 2010, 105(2):168-173.
37. Webb D.R., Meltzer E.O., Finn A.F., et al. Intranasal fluticasone propionate is effective for perennial nonallergic rhinitis with or without eosinophilia. Ann Allergy Asthma Immunol 2002, 88:385-390.